300363 Stock Overview
Engages in the manufacture and sale of small molecule active pharmaceutical ingredients, dosage forms, and biologics to the pharmaceutical companies in China, the United States, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Porton Pharma Solutions Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥15.76 |
| 52 Week High | CN¥21.98 |
| 52 Week Low | CN¥10.91 |
| Beta | 0.18 |
| 1 Month Change | -0.063% |
| 3 Month Change | -10.35% |
| 1 Year Change | -4.72% |
| 3 Year Change | -79.74% |
| 5 Year Change | -37.93% |
| Change since IPO | 63.49% |
Recent News & Updates
Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?
Jan 01
Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%
Nov 14Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues
Sep 30Recent updates
Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?
Jan 01Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%
Nov 14Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues
Sep 30Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?
Sep 25Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?
Jun 26Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically
May 02Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?
Mar 26Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Mar 04Shareholder Returns
| 300363 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.3% | 0.04% | 0.07% |
| 1Y | -4.7% | 8.3% | 18.4% |
Return vs Industry: 300363 underperformed the CN Pharmaceuticals industry which returned 8.3% over the past year.
Return vs Market: 300363 underperformed the CN Market which returned 18.4% over the past year.
Price Volatility
| 300363 volatility | |
|---|---|
| 300363 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.8% |
| 10% least volatile stocks in CN Market | 4.0% |
Stable Share Price: 300363 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300363's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4,300 | Nianfeng Ju | www.porton.cn |
Porton Pharma Solutions Ltd. engages in the manufacture and sale of small molecule active pharmaceutical ingredients, dosage forms, and biologics to the pharmaceutical companies in China, the United States, and Europe. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Porton Pharma Solutions and Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. The company was formerly known as Porton Fine Chemicals Ltd.
Porton Pharma Solutions Ltd. Fundamentals Summary
| 300363 fundamental statistics | |
|---|---|
| Market cap | CN¥8.60b |
| Earnings (TTM) | -CN¥391.43m |
| Revenue (TTM) | CN¥2.76b |
3.1x
P/S Ratio-22.0x
P/E RatioIs 300363 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300363 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.76b |
| Cost of Revenue | CN¥2.22b |
| Gross Profit | CN¥534.89m |
| Other Expenses | CN¥926.32m |
| Earnings | -CN¥391.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 29, 2025
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 19.41% |
| Net Profit Margin | -14.20% |
| Debt/Equity Ratio | 24.7% |
How did 300363 perform over the long term?
See historical performance and comparisonDividends
3.1%
Current Dividend Yield-68%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 01:19 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Porton Pharma Solutions Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Zhu Chen | Citic Securities Co., Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |